BSE Live
Oct 21, 14:55Prev. Close
521.20
Open Price
516.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Oct 21, 14:55Prev. Close
523.40
Open Price
523.40
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
Profit & Loss account of Lincoln Pharmaceuticals (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 623.23 | 571.22 | 504.95 | 468.20 | 414.75 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Revenue From Operations [Net] | 623.23 | 571.22 | 504.95 | 468.20 | 414.75 | |
Total Operating Revenues | 623.23 | 580.55 | 510.31 | 472.12 | 424.19 | |
Other Income | 22.48 | 34.42 | 22.47 | 10.00 | 5.66 | |
Total Revenue | 645.71 | 614.97 | 532.78 | 482.12 | 429.85 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 213.94 | 201.12 | 177.00 | 158.48 | 123.43 | |
Purchase Of Stock-In Trade | 68.54 | 82.91 | 68.64 | 73.67 | 70.31 | |
Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FGWIP And Stock In Trade | 8.84 | -5.70 | -4.24 | -13.57 | 3.99 | |
Employee Benefit Expenses | 112.45 | 102.90 | 93.16 | 70.47 | 60.74 | |
Finance Costs | 1.88 | 1.46 | 2.03 | 1.45 | 1.56 | |
Depreciation And Amortisation Expenses | 12.90 | 10.62 | 9.17 | 8.09 | 7.56 | |
Other Expenses | 117.96 | 99.40 | 86.55 | 87.59 | 78.53 | |
Total Expenses | 536.52 | 492.73 | 432.30 | 386.18 | 346.13 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 109.19 | 122.24 | 100.48 | 95.94 | 83.72 | |
Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Profit/Loss Before Tax | 109.19 | 122.24 | 100.48 | 95.94 | 83.72 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 26.84 | 25.21 | 24.75 | 24.50 | 21.29 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | 0.00 | 3.49 | 1.59 | 0.72 | 0.25 | |
Other Direct Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Tax Expenses | 26.84 | 28.94 | 27.58 | 26.58 | 21.47 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 82.35 | 93.30 | 72.90 | 69.36 | 62.25 | |
Profit/Loss From Continuing Operations | 82.35 | 93.30 | 72.90 | 69.36 | 62.25 | |
Profit/Loss For The Period | 82.35 | 93.30 | 72.90 | 69.36 | 62.25 | |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | -0.03 | |
Consolidated Profit/Loss After MI And Associates | 82.35 | 93.30 | 72.90 | 69.36 | 62.22 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 41.00 | 47.00 | 36.00 | 35.00 | 31.00 | |
Diluted EPS (Rs.) | 41.00 | 47.00 | 36.00 | 35.00 | 31.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 0.00 | 3.00 | 3.00 | 3.00 | 0.00 | |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
07.08.2025
Lincoln Pharma Standalone June 2025 Net Sales at Rs 154.07 crore, up 4.61% Y-o-Y
24.06.2025
Lincoln Pharma Consolidated March 2025 Net Sales at Rs 168.18 crore, up 18.03% Y-o-Y
04.03.2025
Lincoln Pharma Consolidated December 2024 Net Sales at Rs 146.55 crore, up 0.07% Y-o-Y
28.11.2024
Lincoln Pharma Consolidated September 2024 Net Sales at Rs 161.21 crore, up 3.35% Y-o-Y
07.08.2025
Lincoln Pharma Standalone June 2025 Net Sales at Rs 154.07 crore, up 4.61% Y-o-Y
24.06.2025
Lincoln Pharma Consolidated March 2025 Net Sales at Rs 168.18 crore, up 18.03% Y-o-Y
04.03.2025
Lincoln Pharma Consolidated December 2024 Net Sales at Rs 146.55 crore, up 0.07% Y-o-Y
28.11.2024
Lincoln Pharma Consolidated September 2024 Net Sales at Rs 161.21 crore, up 3.35% Y-o-Y